NA
CSTL icon

NewEdge Advisors’s Castle Biosciences CSTL Stock Holding History

NewEdge Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-247
Closed -$6.58K – 3997
2024
Q4 		$6.58K Buy
+247
New +$7.52K ﹤0.01% 3157
2024
Q1 		– Sell
-250
Closed -$5.39K – 3852
2023
Q4 		$5.39K Buy
+250
New +$4.4K ﹤0.01% 3103
2023
Q1 		– Sell
-398
Closed -$9.37K – 3562
2022
Q4 		$9.37K Buy
+398
New +$9.23K ﹤0.01% 2393

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NewEdge Advisors's CSTL Position: Q1 2025 in Review

NewEdge Advisors sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 247 shares — an estimated $6.58K sold.

NewEdge Advisors first reported a position in CSTL in Q4 2022 and held it in 3 quarters. The position peaked at $9.37K in Q4 2022. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • NewEdge Advisors reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • NewEdge Advisors sold 247 Castle Biosciences shares in Q1 2025, an estimated $6.58K.
  • NewEdge Advisors first reported a position in Castle Biosciences in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Castle Biosciences position peaked at $9.37K in Q4 2022.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on NewEdge Advisors's 13F filing for Q1 2025, filed 15 May 2025.